US 12,251,421 B2
Methods for treating cancers using fat specific protein 27 (FSP27) compositions
John J. Kopchick, Athens, OH (US); Vishwajeet Puri, Athens, OH (US); Vishva Sharma, Athens, OH (US); and Reetobrata Basu, Athens, OH (US)
Assigned to Ohio University, Athens, OH (US)
Filed by Ohio University, Athens, OH (US)
Filed on Mar. 26, 2024, as Appl. No. 18/616,600.
Application 18/616,600 is a division of application No. 17/859,490, filed on Jul. 7, 2022, granted, now 11,975,044.
Application 17/859,490 is a division of application No. 16/646,009, granted, now 11,426,445, issued on Aug. 30, 2022, previously published as PCT/US2018/051309, filed on Sep. 17, 2018.
Claims priority of provisional application 62/560,326, filed on Sep. 19, 2017.
Prior Publication US 2024/0269231 A1, Aug. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 38/1761 (2013.01) [A61P 31/00 (2018.01); A61P 35/00 (2018.01)] 12 Claims
 
7. A pharmaceutical composition comprising one or more fat specific protein (FSP27) fragments,
wherein the FSP27 fragment is selected from:

OG Complex Work Unit Chemistry
optionally together with one or more inert carriers and/or diluents; and
further comprising at least one chemotherapeutic agent, wherein the chemotherapeutic agent is one or more of: sorafenib tosylate, cisplatin, paclitaxel, gemcitabine, vemurafenib, dabrafenib, linsitinib, crizotinib, and cabozantinib.